Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis

Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression‐free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.

[1]  M. Kohli,et al.  Response criteria in oncologic imaging: review of traditional and new criteria. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[2]  David W. Henry,et al.  Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.

[3]  M. Carli,et al.  Hydroxyurea Treatment Can Avoid the Need for Aggressive Surgery in Pediatric Fibromatosis , 2013, Journal of pediatric hematology/oncology.

[4]  P. Terrier,et al.  The treatment of desmoid tumors: a stepwise clinical approach. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Blay,et al.  Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Blay,et al.  Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Dafydd G. Thomas,et al.  Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial , 2010, Clinical Cancer Research.

[8]  C. Antonescu,et al.  Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis , 2010, Clinical Cancer Research.

[9]  A. Ferrari,et al.  Aggressive fibromatosis in children and adolescents , 2009, Cancer.

[10]  Robin L. Jones,et al.  Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.

[11]  M. Bertagnolli,et al.  Multimodality treatment of mesenteric desmoid tumours. , 2008, European journal of cancer.

[12]  S. Skapek,et al.  Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Niemeyer,et al.  Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin , 2004, Oncology Research and Treatment.

[14]  N. Schachar,et al.  Desmoid tumors: A novel approach for local control , 2002, Journal of surgical oncology.

[15]  T. Merchant,et al.  Long-term results with radiation therapy for pediatric desmoid tumors. , 2000, International journal of radiation oncology, biology, physics.

[16]  M. Hameed,et al.  Desmoid fibromatosis in children and adolescents: a conservative approach to management. , 2013, Journal of pediatric surgery.

[17]  J. Blay,et al.  Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Zaenglein.  Aggressive Fibromatosis in Children and Adolescents: The Italian Experience , 2011 .

[19]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[20]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.